Blood donor screening in the Netherlands: Universal anti-HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing
- PMID: 33899233
- DOI: 10.1111/trf.16420
Blood donor screening in the Netherlands: Universal anti-HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing
Abstract
Background: In the Netherlands, blood donor screening for hepatitis B virus (HBV) consists of HBsAg screening since the 1970s, HBV DNA minipool testing (MP-NAT) since 2008, and anti-HBc screening since 2011. Anti-HBc reactivity causes deferral only if anti-HBs titers are <200 IU/mL, or when anti-HBc was acquired during follow-up.
Study design and methods: Over 5.5 million donations from 582,459 Dutch donors were screened for HBV DNA, HBsAg, anti-HBc, and, if anti-HBc positive, also for anti-HBs. The added value, expressed as the yield of (potentially) infectious and/or recent HBV infections versus unnecessary donor loss, was evaluated for each of the three HBV screening tests.
Results: HBV donor screening identified 89 HBV-infected donors with at least two reactive HBV markers (MP-NAT, HBsAg and/or anti-HBc). Single HBV-marker yield was: 5 MP-NAT-only, 0 HBsAg-only, and 20 anti-HBc-only donors. In addition, anti-HBc screening yielded 1,067 potentially infectious donors at risk for occult HBV infection (OBI). In total, 4,126 (0.71%) donors were anti-HBc-reactive at first-time screening, and 1,098 (0.19%) seroconverted during follow-up. Anti-HBc-related donor loss was limited to 2,627 (0.45%) donors using anti-HBs titers and two-strike programs. Donor loss due to MP-NAT and HBsAg screening was extremely low: 0 and 128 donors, respectively.
Conclusion: HBV donor screening could be limited to MP-NAT and anti-HBc screening. MP-NAT and anti-HBc improved blood safety by intercepting infectious donations from donors with recent infection or OBI, while HBsAg did not. Unnecessary donor loss related to anti-HBc screening is substantial but does not endanger the continuity of the blood supply.
Keywords: infectious disease testing; transfusion transmitted disease-hepatitis.
© 2021 AABB.
Similar articles
-
The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country.Transfusion. 2015 Jun;55(6):1206-13. doi: 10.1111/trf.12962. Epub 2014 Dec 15. Transfusion. 2015. PMID: 25494685
-
Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value?Transfusion. 2012 Feb;52(2):440-6. doi: 10.1111/j.1537-2995.2011.03283.x. Epub 2011 Aug 2. Transfusion. 2012. PMID: 21810101
-
Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection.Transfusion. 2014 Aug;54(8):2084-91. doi: 10.1111/trf.12556. Epub 2014 Mar 20. Transfusion. 2014. PMID: 24650170
-
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?Transfus Clin Biol. 2004 Feb;11(1):26-32. doi: 10.1016/j.tracli.2003.12.003. Transfus Clin Biol. 2004. PMID: 14980546 Review.
-
New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.Mol Diagn Ther. 2006;10(2):77-91. doi: 10.1007/BF03256447. Mol Diagn Ther. 2006. PMID: 16669606 Review.
Cited by
-
Evaluating the cost-effectiveness of low-level HBV DNA screening in occult hepatitis B infection donors: A study from Shandong Blood Center, China.Heliyon. 2023 Jul 25;9(8):e18609. doi: 10.1016/j.heliyon.2023.e18609. eCollection 2023 Aug. Heliyon. 2023. PMID: 37560659 Free PMC article.
-
Prevalence of Occult Hepatitis B Virus Infection in Blood Donors with Negative ID-NAT in Switzerland.Transfus Med Hemother. 2022 Jul 6;49(6):338-345. doi: 10.1159/000525480. eCollection 2022 Dec. Transfus Med Hemother. 2022. PMID: 36654973 Free PMC article.
-
Seroprevalence of Transfusion Transmissible Infections and Associated Risk Factors in Hospitalized Patients before Transfusion in Jinling Hospital Nanjing University: A Three-Year Retrospective Study.Pathogens. 2022 Jun 20;11(6):710. doi: 10.3390/pathogens11060710. Pathogens. 2022. PMID: 35745563 Free PMC article.
-
Prevalence of antibody to hepatitis B surface antigen among qualified blood donors in Nanjing, China.Hum Vaccin Immunother. 2023 Dec 31;19(1):2206774. doi: 10.1080/21645515.2023.2206774. Hum Vaccin Immunother. 2023. PMID: 37103976 Free PMC article.
-
Retrospective analysis of quality monitoring indexes of Grifols Panther nucleic acid detection system.Medicine (Baltimore). 2025 Jul 25;104(30):e43463. doi: 10.1097/MD.0000000000043463. Medicine (Baltimore). 2025. PMID: 40725892 Free PMC article.
References
REFERENCES
-
- Slot E, Janssen MP, Marijt-van der Kreek T, Zaaijer HL, van de Laar TJ. Two decades of risk factors and transfusion-transmissible infections in Dutch blood donors. Transfusion. 2016;56:203-14.
-
- van de Laar T, Marijt-van der Kreek T, Molenaar-de Backer MW, Hogema BM, Zaaijer HL. The yield of universal antibody to hepatitis B core antigen donor screening in The Netherlands, a hepatitis B low-endemic country. Transfusion. 2015;55:1206-13.
-
- Lieshout-Krikke RW, Molenaar-de Backer MW, van Swieten P, Zaaijer HL. Surface antigen-negative hepatitis B virus infection in Dutch blood donors. Eur J Clin Microbiol Infect Dis. 2014;33:69-77.
-
- Lieshout-Krikke RW, van Kraaij MG, Danovic F, Zaaijer HL. Rare transmission of hepatitis B virus by Dutch donors with occult infection. Transfusion. 2016;110:301-9.
-
- Seed C, Allain JP, Lozano M, Laperche S, Gallian P, Gross S, et al. International forum on occult hepatitis B infection and transfusion safety. Vox Sanquin. 2019;114:397-406.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical